This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Morari, E. C. Articles by Ward, L. S. Search for Related Content PubMed PubMed Citation Articles by Morari, E. C. Articles by Ward, L. S.

The Null Genotype of Glutathione S-Transferase M1 and T1 Locus Increases the Risk for Thyroid Cancer¹

Laboratory of Cancer Molecular Genetics, Department of Medicine, State University of Campinas, 13085-857 Campinas, São Paulo, Brazil

Susceptibility to chemical carcinogens plays an important role in the development of most cancers. Several polymorphisms of human drug-metabolizing enzymes influence this individual susceptibility. The genes that encode the isoenzymes of the glutathione s-transferase (GST) system present a polymorphic inheritance. The GST mu 1 (GSTM1) and GST theta 1 (GSTT1) genes have a null allele variant in which the entire gene is absent. The null genotype for both enzymes has been associated with many different types of tumors. To look for the influence of the inheritance pattern of these enzymes on thyroid cancer risk, we used a triplex PCR that included ß-globin gene as a DNA quality control to compare 300 normal individuals of our population to 116 goiter patients. There were 49 cases of benign and 67 cases of malignant nodules: 50 papillary and 17 follicular carcinomas. Comparison between thyroid tumor specimens and normal corresponding samples of 35 cancer patients demonstrated identical patterns, suggesting that the GST system is not involved in the process of follicular dedifferentiation. There was no statistical difference between the prevalence of the deleted alleles in the normal individuals and in the goiter patients. However, papillary carcinoma patients (10%) and follicular carcinoma patients (17%) presented a higher prevalence of the null genotype than the normal population individuals (5%; P < 0.05). We found a 2.6 increased risk of thyroid cancer in individuals with the GSTT1 and GSTM1 combined null inheritance, suggesting that this genotype may be associated with an increased susceptibility to thyroid cancer.

This article has been cited by other articles:

				A. C.T. Guilhen, N. E. Bufalo, E. C. Morari, J. L. Leite, L. V.M. Assumpcao, A. J.A. Tincani, and L. S. Ward Role of the N-Acetyltransferase 2 Detoxification System in Thyroid Cancer Susceptibility Clin. Cancer Res., January 1, 2009; 15(1): 406 - 412. [Abstract] [Full Text] [PDF]

				N. E Bufalo, J. L Leite, A. C T Guilhen, E. C Morari, F. Granja, L. V M Assumpcao, and L. S Ward Smoking and susceptibility to thyroid cancer: an inverse association with CYP1A1 allelic variants Endocr. Relat. Cancer, December 1, 2006; 13(4): 1185 - 1193. [Abstract] [Full Text] [PDF]

				T. Ho, C. Zhao, R. Zheng, Z. Liu, Q. Wei, and E. M. Sturgis Glutathione s-transferase polymorphisms and risk of differentiated thyroid carcinomas: a case-control analysis. Arch Otolaryngol Head Neck Surg, July 1, 2006; 132(7): 756 - 761. [Abstract] [Full Text] [PDF]

				Y. Zhang and G. B. Gordon A strategy for cancer prevention: Stimulation of the Nrf2-ARE signaling pathway Mol. Cancer Ther., July 1, 2004; 3(7): 885 - 893. [Abstract] [Full Text] [PDF]